Kisspeptin Peptide: Structure and Isoforms

The kisspeptin peptide family is encoded by the KISS1 gene. The gene produces a 145-amino-acid precursor protein that is processed to yield four principal fragments: KP-54 (54 amino acids), KP-14, KP-13, and KP-10. All four isoforms share a conserved C-terminal decapeptide sequence ending in the RF-amide motif (Arg-Phe-NH₂) required for KISS1R binding. The minimal fully active fragment is KP-10 (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂; molecular weight 1302.5 Da).[1][4]

KP-54 (molecular weight 6142 Da) is the primary endogenous isoform detected in human plasma and in hypothalamic tissue. Its larger size provides approximately 8-fold greater resistance to endopeptidase cleavage compared to KP-10, accounting for the corresponding difference in plasma half-life (~32 min versus ~4 min).[12]

All kisspeptin isoforms are classified as neuropeptides within the RF-amide peptide superfamily, a group of peptides sharing the C-terminal -Arg-Phe-NH₂ sequence. KISS1R (GPR54) is the only confirmed high-affinity receptor for kisspeptin.

What does kisspeptin peptide do?

As the master upstream regulator of the reproductive hormone axis, kisspeptin activates KISS1R on GnRH neurons in the hypothalamus, initiating the hormonal cascade that governs puberty onset, fertility, and reproductive cycling.

The signaling sequence from a single kisspeptin-KISS1R binding event: Gq/11 activation → phospholipase C → IP3 generation → intracellular calcium release → GnRH-neuron depolarization (~6 mV, ~21 min duration) → pulsatile GnRH secretion → pituitary LH and FSH release → gonadal testosterone, estradiol, and progesterone production.[4]

The same molecule also has a separately documented role as a metastasis suppressor in solid tumors,[17][19] a function independent of its reproductive axis activity and mediated by different downstream pathways in epithelial and mesenchymal cell contexts.

How was kisspeptin discovered?

The KISS1 gene was cloned in 1996 at the Milton S. Hershey Medical Center in Hershey, Pennsylvania, as a melanoma metastasis suppressor gene. Stable KISS1 transfection suppressed metastasis of human melanoma C8161 cells by more than 95% in nude mice without affecting tumorigenicity (Lee 1996, J Natl Cancer Inst).[17] The name "KiSS-1" was coined partly as a reference to the city of Hershey, Pennsylvania — known for its chocolate — and the gene's discovery there.

The peptide product of KISS1 was independently characterized in 2001 as a ligand for the orphan receptor GPR54, originally designated "metastin" for its metastasis-suppressive properties before its reproductive function was established.

The reproductive role was identified in 2003. Two independent research groups simultaneously published landmark findings: Seminara et al. (NEJM) identified inactivating GPR54 mutations in patients with idiopathic hypogonadotropic hypogonadism and absent puberty, and confirmed the phenotype in Gpr54-knockout mice.[1] De Roux et al. (published concurrently) independently reached the same conclusion. This established that kisspeptin signaling through GPR54 is required for normal human puberty — not merely a contributor, but a necessary component.

What is the KISS1 gene?

KISS1 (Gene ID: 3814) is located on human chromosome 1q32. It encodes the 145-amino-acid kisspeptin precursor protein. The gene was first described as a melanoma metastasis suppressor (Hershey, Pennsylvania, 1996)[17] before its reproductive role was discovered through the KISS1R/GPR54 mutation findings published in 2003[1] and the KISS1 inactivating mutation study published in 2012 (Topaloglu 2012, NEJM).[3]

KISS1 expression in the hypothalamus is concentrated in two neuronal populations: KNDy neurons in the arcuate nucleus (which co-express neurokinin B and dynorphin A and constitute the GnRH pulse generator) and neurons in the anteroventral periventricular nucleus (which mediate the positive-feedback LH surge in females).[15]

KISS1 expression in peripheral tissues — thyroid, breast, pancreas, liver — has anti-metastatic properties in most studied cancer types,[19] though the receptor-downstream pathways and clinical implications differ substantially from the hypothalamic reproductive function.

What is metastin?

Metastin is the original name given to the 54-amino-acid KISS1 peptide product when it was first characterized as a ligand for the orphan receptor GPR54 and shown to suppress melanoma cell invasion. When it became clear that this 54-amino-acid peptide is the primary endogenous kisspeptin isoform — and that kisspeptin signaling drives the HPG axis — the name kisspeptin-54 (KP-54) became standard. Metastin is used interchangeably with kisspeptin-54 in the older literature.

Abstract illustration comparing a short peptide chain and a longer peptide chain as glowing molecular abstractions

KP-10

10

Amino acids · 1302.5 Da

KP-54

54

Amino acids · 6142 Da

About this site. Kisspeptin Research is an independent editorial project. We summarize the peer-reviewed literature on kisspeptin. We are not a clinic, do not provide medical advice, and do not sell any product. See the full editorial statement below.

About Kisspeptin Research

Kisspeptin Research is an independent editorial project that publishes summaries of the peer-reviewed research literature on kisspeptin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name "kisspeptinresearch.com" is editorial framing — a position this publisher occupies relative to the literature, not a claim about clinical services offered. We summarize published research; we do not conduct it, fund it, or profit from it.

Every quantitative claim on this site is cited to a peer-reviewed source. The full citation index is at /references. If a citation is broken or a claim cannot be verified, use the contact page to let us know.

Kisspeptin is an investigational research peptide. No content on this site constitutes medical advice, clinical guidance, or a recommendation to self-administer any compound.